Regeneron Is Playing Defense With Capital Allocation
Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
Jefferies Sticks to Their Buy Rating for Regeneron (REGN)
In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...
abc7NY12d
Passionate Long Island senior selected as Regeneron finalist for pancreatic cancer research
LONG ISLAND, New York (WABC) -- Long Island is well represented this year at the prestigious Regeneron Science Talent Search. The annual search is the longest running of its kind, and seeks the ...
Yahoo20d
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...
pharmaphorum6d
Regeneron, CytomX announce bispecific therapeutics for cancer collab
Using CytomX’s Probody and Regeneron’s Veloci-Bi platforms, the collaboration and licensing agreement aims to enable the development of investigational next-generation bispecific immunotherapies.
Reuters24d
Regeneron Pharmaceuticals Inc
2024 Regeneron Pharmaceuticals has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court. Regeneron ...